Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogenous disease, with distinct disease patterns. In advanced disease patients remain breathless despite proven therapies such as maximal bronchodilation and pulmonary rehabilitation.
Lung volume reduction surgery (LVRS) has been shown to have maximum benefit in patients who are hyperinflated with heterogenous emphysema, resulting in improvements in lung function, exercise capacity, health status and survival (1) .
Despite the proven efficacy and cost-effectiveness(2) of LVRS there remains a low rate of referral for assessment (3) . There are an estimated 16,000 potentially eligible patients in the UK(4), yet only 89 VATS LVRS procedures were performed in the UK in 2013-14 (5) . One of the major barriers to referral has been the perception by physicians of the high risk to the procedure(6), with an peri-operative mortality rate of 5.2% reported in those without high risk and 7.9% in all patients (1) .However, individuals who undergo LVRS will differ in their peri-operative risk and there may be added value in the ability to present an objective, more individualised risk to a patient prior to surgical intervention. This may aid the multidisciplinary team (MDT) in decision about eligibility for LVRS and alternative treatment strategies, as well as assist with shared decision making in the consultation with the patient. It is also unknown if patients at differing peri-operative risk from LVRS confer a similar benefit in improvement, which may influence the risk-benefit balance of the intervention.
The purpose of this study was to identify preoperative factors that are predictive of peri-operative mortality following LVRS. Using these risk factors we aimed to develop a scoring system to allow a better risk stratification that may aid patient selection, MDT discussion and their decision by individualising their perioperative risk. We then aimed to assess the effectiveness of LVRS in each risk group and present its integration into clinical practice.
Methods

Study Design
This was prospectively collected data from a single centre cohort of patients undergoing LVRS (Glenfield Hospital, Leicester, UK) as part of clinical practice.
Patients with COPD were considered for LVRS if they were symptomatic with breathlessness despite optimised medical management, including pulmonary rehabilitation, were hyperinflated using body plethysmography (TLC >100% predicted, and RV >150% predicted or RV/TLC ratio >55%) and had evidence of emphysema heterogeneity, defined using quantitative radionuclide scintigraphy as a hypoperfused target area (contributing to less than 10% of the perfusion to that lung). All patients who underwent LVRS were discussed at a dedicated MDT as previously described, consisting a minimum of respiratory physician, thoracic surgeon and radiologist (7) . Patients were routinely referred for pulmonary rehabilitation prior to MDT discussion. A TLCO of <20% was not considered an absolute contraindication to LVRS, and were considered if FEV1>20% predicted and written informed consent was obtained of high risk of surgery. Only patients who underwent unilateral video-assisted thoracoscopy (VATS) were included in the analysis(8), and included patients undergoing second contralateral LVRS at a separate time to initial LVRS. No patients underwent single stage bilateral LVRS during the analysis period. Contralateral LVRS was considered when deterioration was noted in patient perception of breathlessness and exercise capacity (9) .
Outcome Measures
The primary endpoint was mortality at 90 days. Mortality was captured from a dedicated prospective database, hospital records and GP records. All patients undergoing LVRS were followed up at a dedicated outpatient clinic every three months following surgery for one year. In those who died date of death was recorded and postoperative interval calculated.
Demographics were collected at outpatient clinic prior to surgery. Lung function was performed at Glenfield Hospital including static lung volumes estimated from body box plethysmography and diffusion capacity. Lung function measures were performed prior to MDT discussion, and at three, six and twelve months following LVRS, at time of outpatient clinic review. Height and weight were measured at the outpatient clinic prior to surgery and body mass index (BMI) calculated. Capillary blood gases were collected from arterialised ear lobes. Health status was measured using the Euroqol EQ-5D at baseline and during follow up clinic appointments or postal survey.
Statistical Analysis
All data were prospectively collected on a departmental database and retrospectively analysed. Statistical analysis was performed using STATA 13 (StataCorp, USA).
Baseline characteristics between survivors and patients who were dead at 90 days were compared using independent samples t-test, Mann-Whitney U test and chi squared test for parametric, non-parametric and categorical data respectively.
Factors associated with 90 day mortality were identified by univariate logistic regression. Multivariate analyses with the selected factors identified from the univariate analysis (selected using a p value cut off of 0.1) were conducted with binary logistic regression using a backward stepwise approach. Complete data for the multivariate model was available for 218/237 (92%) of the LVRS procedures.
Continuous variables were grouped (FEV1, FVC, RV/TLC ratio divided at their mean.
TLCO at cut-off based on NETT trial(1), BMI at World Health Organisation definition of underweight), allowing a risk score to be derived. Continuous variables were categorised to allow for allocation of risk score. Cut-off values were either taken at the mean, median or at an internationally recognised value. For the derivation of the risk score a weighting was allocated to each risk factor based on the beta coefficient.
Performance of the tool was assessed using receiver operator characteristic (ROC) curves. The area under the ROC curve (AUROC) was used to describe the overall performance of the score. Time to death was analysed using Kaplain-Meier.
Differences between the three groups were compared using ANOVA.
The score derived from the first cohort was introduced to the LVRS MDT and was tested in a second cohort at the same site, separated by time. Performance of the derived score was tested using AUROC. 
Derivation of Risk Score
Three independent factors were identified from the multivariate model-BMI "B", FEV1 "F" and gas transfer "G". Each factor was assigned a risk score based on its beta coefficient (nearest whole number) and then added together to produce a total score-the "Glenfield BFG" score. Table 3 The predictive scores were divided into 3 groups: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-5) groups. 46% (n=100), 41% (n=89) and 13%
(n=29) of patients were classified in the low, moderate and high risk groups respectively. Kaplan-Meier survival with separate curves for the 3 groups up to one year is shown in figure 2. Significant differences in survival were seen between the three groups (p<0.01). Mortality rates at 30 days, 90 days and one year for the three groups are shown in table 4.
In addition to 90 day mortality, the Glenfield BFG score was tested at both shorter and longer time points. The AUROC for the different risk groups (low, moderate and high) at 30 days was 0.67 and 0.80 at one year.
Clinical response of Different Risk Groups
Lung function was assessed at three months following LVRS. Significant increases in FEV1 % predicted (p<0.05) and reduction in residual volume (p<0.01) were seen at 3 months following LVRS. There was no significant difference in lung function improvement in the different risk groups (figure 3).
Health status was measured using the EQ-5D. figure 5 .
Discussion
In this study we demonstrate that mortality following LVRS is acceptably low in selected groups, who can be identified from an individualised risk assessment score.
Almost half (46%) of our patients in this cohort were classified in the lowest risk group. This population had only a 1% mortality at 90 days, which remained similar at one year. This study highlights that for many patients who undergo LRVS it is of considerable lower risk than is often perceived(3),which may deter many patients and referrers from considering LVRS.
We also show that routinely collected measures pre-operatively can provide a more individualised risk assessment. This can be utilised using a simple scoring method-"the Glenfield BFG score" -which adds prognostic information. This multidimensional tool was superior than any of the individual factors for death. This is important as a patient may be considered high risk based on one measure, but have low risk for others, which influences overall risk.
All risk groups showed significant physiological benefit and improvements in health status following LVRS, with no inter-group difference . This suggests that whilst individuals may vary in their risk for LVRS, even high risk patients may benefit from therapy. Whilst, the Glenfield BFG score successfully identified patients at risk of death following LVRS, this does not measure factors which suggest benefit. Many of these have been previously identified in the NETT trial such as hyperinflation, disease heterogeneity and low exercise capacity.
We did see a significant worsening of symptoms in the pain domain of the EQ5D post LVRS. This is not surprising and has been described previously (10) and is likely to improve as the time from surgery increases.
The Glenfield BFG score is practical to implement in the LVR MDT with the score successfully implemented in 2013, following its derivation. Fewer patients in the high risk group underwent LVRS following implementation of the Glenfield BFG score (4% versus 13%). This would suggest it is a useful tool for the MDT and patients to inform decisions around risks of LVRS and influences decisions around LVRS, though it is unknown if this is during the MDT process or patient decision. However, patients at high risk still derived benefits in lung function and health status similar to other groups from LVRS and therefore careful discussion between clinicians and patients about the balance of potential risks and benefits requires careful consultation.
It is unsurprising that patients with the least severe disease markers have the lowest risk, and the factors identified are known risk factors for LVRS. A TLCO of <20% predicted is considered a relative contraindication for surgery based on the NETT trial. This study agrees with previous work that a low TLCO is an independent predictor of mortality though this study would suggest a TLCO <20% predicted should be considered a relative contraindication depending on other risk factors. Our cut-off of 0.71L for FEV1 is similar to the 20% predicted previous published high risk for LVRS(6). The cut-off in our study was approximately 26% predicted. However, we used absolute values rather than percent predicted. This is because calculation of predicted FEV1 requires height and weight, and therefore interacts with BMI in the Glenfield BFG score, reducing its independence.
However, the Glenfield BFG score provides an objective and multi-dimensional system of scoring disease severity, superior to its individual elements. Given that patients with less severe markers of disease have a better prognosis and yet still gain significant benefit from LVRS, then earlier consideration of LVRS could be considered, especially if the potential risks are lower.
Similarly identifying high risk patients is important as it is important to counsel them appropriately to the risks of the intervention, as other strategies may be more appropriate. This may include optimisation of symptom control, through palliative care input including alternative management of refractory dyspnoea or consideration of lung transplantation. However, this risk may be acceptable to patients; postoperative lung function and clinical outcome are as good as the lower risk patients.
Therefore, we believe that LVRS should still be considered, though a higher Glenfield score may be considered a strong relative contraindication and patients' counselled appropriately and are aware of the risks involved. Those that were in the high risk group typically had low TLCO and a low FEV1. The high risk group identified in this risk score had fulfilled the criteria for LVRS including heterogenous emphysema and absence of pulmonary hypertension.
A number of scoring systems and risk stratification tools exist for COPD. This is the first objective scoring system for risk of LVRS, with other scores typically focussing on long term outcome(11) or exacerbation risk (12) . Other research has previously identified markers of high risk for LVRS, including homogenous disease, high perfusion ratio, low FEV1 (<20% predicted), and low TLCO (<20% predicted)(1, 6).
These factors have led to changes in patient selection for LVRS. For example, all patients in this cohort for example had heterogeneous emphysema with low perfusion ratio, though in this cohort TLCO <20% predicted was not considered an absolute contraindication.
The differences in mortality between the three risk groups were seen in the period following LVRS, with no separation in mortality after approximately 2 months ( figure   2 ). This would suggest that the Glenfield BFG score is a true marker of perioperative risk, rather than a marker of overall disease severity.
There are a number of potential mechanisms identified by the Glenfield BFG score that increase peri-operative adverse events. Malnutrition, measured with BMI in this study, leads to increased susceptibility to infection and poor wound healing.
Specifically in COPD poor nutritional status(11), frailty(13) and sarcopenia (14) are all associated with worse outcome. The Glenfield BFG score is also likely to identify patients at higher risk of prolonged air leak (PAL), as the higher risk patients had lower FEV1 and more severe emphysema, which are known risk factors for PAL (15) .
PAL may then subsequently lead to increased morbidity and mortality (16, 17) .
It is unknown if the Glenfield Score is applicable to newer lung volume reduction techniques (eLVR), such as endobronchial valves (18, 19) or coils (20, 21) . The operative procedure in eLVR differs considerably from LVRS and it therefore may alter peri-operative risk. However, the risk factors identified in the Glenfield BFG score may also be relevant for eLVR. Testing of the score following eLVR is therefore needed to validate it in this specific interventional population.
We acknowledge a number of limitations in this study. This is a retrospective cohort, although the data were collected prospectively. However, there will be bias within patient selection, though this has been standardised through a MDT and included high risk patients. We would suggest that the role of the Glenfield BFG score would be to aid the MDT decision and allow patients to make a more informed judgement of risks. The data collection was conducted over a long period of time, and over time practice changes which may alter mortality rate. However, LVRS is not a common procedure and contemporary cohorts of comparable size are not available. A lack of external contemporary cohorts mean that we have not been able to provide external validation for the Glenfield BFG score, though this will be able to be tested prospectively with new national LVR registries, such as currently being established in the UK.
In summary we have demonstrated and validated that using a simple scoring system, the "Glenfield BFG score", we can provide a more accurate peri-operative mortality risk for LVRS. The most frequent group were classified as low risk (mortality risk 1%), which may increase LVRS uptake. Clinical benefit post-LVRS was seen in all risk groups and the score was successfully integrated into the LVR [4] [5] 
